DSpace university logo mark
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > 030 医学部 > 030 紀要 > Acta Medica Nagasakiensia > Volume 34, No. 1 >

4'Epidoxorubicin (Epirubicin) as A Single Agent in Advanced Primary Hepatocellular Carcinoma

ファイル 記述 サイズフォーマット
acta34_01_19_t.pdf276.76 kBAdobe PDF本文ファイル

タイトル: 4'Epidoxorubicin (Epirubicin) as A Single Agent in Advanced Primary Hepatocellular Carcinoma
著者: Tan, Y.O / Lim, F
発行日: 1989年 3月
引用: Acta Medica Nagasakiensia. 1989, 34(1), p.65-68
抄録: 4'-Epidoxorubicin (Epirubicin) is a new anthracycline analogue which has activity in a variety of cancers. Advanced primary hepatocelluar carcinoma is a rapidly fatal neoplasm. Studies with doxorubicin (Adriamycin) in Africa and Asia have shown a response rate around 30-50% with modest gains in median survivals in patients who responded. We report here our experience with epirubicin in advanced primary hepatocellular carcinoma. We treated 13 patients with advanced primary hepatocellular carcinoma with epirubicin using a dose schedule of 60mg/m2 at the beginning and gradually escalated to 90mg/m2 as tolerated. All patients had no prior chemotherapy. Median age was 51 years with range of 31 to 70 years. Cardiotoxicity was serially monitored with radionuclide multigated left ventriculogram. Objective responses were observed in 3 (23%) patients of the 13 evaluable patients. The median duration of these responders was 30 weeks (range 20 to 42). The overall median survival was 11 weeks. Two patients had cardiotoxicity as measured by a significant fall in left ventricular ejection fraction. The toxicities are much less than doxorubicin and better tolerated. We feel that epirubicin has definite activity in primary hepatocellular carcinoma even in patients with advanced disease.
URI: http://hdl.handle.net/10069/17543
ISSN: 00016055
資料タイプ: Departmental Bulletin Paper
原稿種類: publisher
出現コレクション:Volume 34, No. 1

引用URI : http://hdl.handle.net/10069/17543



Valid XHTML 1.0! Copyright © 2006-2015 長崎大学附属図書館 - お問い合わせ Powerd by DSpace